Stock Evaluator: Vivos Therapeutics, Inc. (VVOS)

Vivos Therapeutics, Inc. VVOS

$0.30 0.02 6.41%
August 21, 2026 4:00:00 PM EST November 10, 2021 Volume: 121,510
After Hours: $120.37   0.15  |  0.12% November 10, 2021 7:59 PM EST Volume: 72,713
USD NASD | DELAYED PRICE
SECTOR INDUSTRY
Health Care Health Care Providers & Services

A+ Stock Grade Summary:

VALUE:
GROWTH:
MOMENTUM:
EPS REVISIONS:
QUALITY:
COMPANY SUMMARY
Vivos Therapeutics, Inc. operates as a medical technology and healthcare services company that develops and commercializes treatment modalities for patients with dentofacial abnormalities, obstructive sleep apnea (OSA), and snoring in adults. It offers The Vivos Method, a non-invasive, non-surgical, non-pharmaceutical, multi-disciplinary treatment modality for the treatment of dentofacial abnormalities, OSA, and snoring. The company also offers VivoScore Program, a screening and home sleep test in adults and children. It markets and sells its appliances, and related treatments and services to licensed professionals, primarily general dentists in the United States and Canada. The company was formerly known as Vivos BioTechnologies, Inc. and changed its name to Vivos Therapeutics, Inc. in March 2018. The company was founded in 2016 and is based in Littleton, Colorado.

Commentary & Analysis


Financial Summary

Share Statistics VVOS Industry
Median
Percentile
(All Stocks)
Market Cap (Mil) $3.9 $1,982.5 2%
Shares Out (Mil) 17.7 77.7 28%
Institutional Ownership 84.1% 86.1% 52%
Float (Mil) 11.4 52.1 21%
Beta na 0.75 na
Avg Daily Volume (000s) 1,334 637 75%
Price Change
(52-week)
(93.5%) 79.7% 3%
Growth VVOS Industry
Median
Percentile
(All Stocks)
Sales (5yr) 5.8% 10.9% 40%
Net Income (5yr) (11.9%) (1.6%) 27%
EPS (5yr) 43.2% 0.3% 90
Dividends (5yr) 0.0% 0.0% 0%
Cash Flow (5yr) (15.0%) (17.9%) 52%
Estimates Qtrly Current
Fiscal
Year
Next
Fiscal
Year
# of Estimates 4 4 3
Current EPS ($0.303) ($1.343) ($0.823)
Month Ago EPS ($0.303) ($1.393) ($0.790)
# Rev Up 0 0 0
# Rev Down 1 2 1
Three Months Ago EPS ($0.253) ($1.153) ($0.350)
Year/Year Chg (2.3%) (34.8%) na
Financials VVOS Industry
Median
Percentile
(All Stocks)
Sales (TTM) (Mil) $21 $1,504 13%
Net Income (TTM) (Mil) ($26) $28 22%
EPS (TTM) ($1.827) $0.200 15%
Operating Cash Flow (TTM) (Mil) ($17) $162 16%
Net Cash Flow (TTM) (Mil) ($3) $9 37%
Long-Term Debt (Q1) (Mil) $4 $338 23%
Enterprise Value (Q1) (Mil) na $2,416 na
Valuation VVOS Industry
Median
Percentile
(All Stocks)
P/B na 2.79 na
P/E na 25.8 na
Dividend Yield 0.0% 0.0% 0%
PEG (5yr hist) na 1.2 na
Ratios VVOS Industry
Median
Percentile
(All Stocks)
Gross Margin 61.9% 27.8% 74%
Net Margin (121.8%) 1.2% 7%
ROA (101.5%) 2.2% 5%
ROE na 7.2% na
Liabilities to Assets 116.5% 58.6% 96%
F-Score 4 5 34%

Vivos Therapeutics, Inc. did not pass any screens on 8/20/2026.

Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.

Ⓒ 2026 American Association of Individual Investors